Introduction
Nasal decongestants are drugs used to relieve nasal airway obstruction by vasoconstriction of nasal mucosal blood vessels. This concise guide for B.Pharm students covers topical decongestants (oxymetazoline, xylometazoline), systemic agents (pseudoephedrine, phenylephrine), mechanism of action as alpha-adrenergic agonists, pharmacokinetics, formulations, and common adverse effects such as rebound congestion (rhinitis medicamentosa), tachyphylaxis, hypertension, insomnia, and urinary retention. Emphasis is placed on contraindications, drug interactions (MAOIs, antihypertensives), pediatric and pregnancy considerations, and preservative-related irritation. Understanding these aspects helps safe clinical use and counseling. Now let’s test your knowledge with 30 MCQs on this topic.
Q1. Which mechanism primarily explains the decongestant effect of topical agents like oxymetazoline?
- Beta-2 adrenergic agonism causing bronchial dilation
- Alpha-1 adrenergic receptor-mediated vasoconstriction of nasal mucosa
- Histamine H1 receptor antagonism reducing inflammation
- Anticholinergic blockade reducing glandular secretion
Correct Answer: Alpha-1 adrenergic receptor-mediated vasoconstriction of nasal mucosa
Q2. Which systemic decongestant is most commonly restricted because it can be used to manufacture methamphetamine?
- Pseudoephedrine
- Phenylephrine
- Oxymetazoline
- Ephedrine
Correct Answer: Pseudoephedrine
Q3. Rhinitis medicamentosa (rebound congestion) is most commonly associated with which property of topical decongestants?
- Long systemic half-life
- Preservative-induced allergic rhinitis
- Prolonged topical alpha-receptor downregulation and tachyphylaxis
- Direct epithelial cytotoxicity causing permanent damage
Correct Answer: Prolonged topical alpha-receptor downregulation and tachyphylaxis
Q4. Which adverse effect is especially important to monitor when a patient on MAO inhibitors uses systemic pseudoephedrine?
- Hypoglycemia
- Severe hypertension and hypertensive crisis
- Bradycardia
- Hepatotoxicity
Correct Answer: Severe hypertension and hypertensive crisis
Q5. Which preservative in nasal sprays has been implicated in mucosal irritation and ciliary dysfunction?
- Sodium chloride
- Benzalkonium chloride
- Glycerin
Correct Answer: Benzalkonium chloride
Q6. Which decongestant has poor oral bioavailability and is often criticized for low efficacy in oral OTC formulations?
- Pseudoephedrine
- Phenylephrine
- Naphazoline
- Xylometazoline
Correct Answer: Phenylephrine
Q7. Topical nasal decongestants are preferred over systemic agents for acute local congestion primarily because:
- They have no systemic absorption at all
- They act faster and achieve higher local concentration with fewer systemic effects
- They are cheaper than oral agents
- They last longer in action systemically
Correct Answer: They act faster and achieve higher local concentration with fewer systemic effects
Q8. Tachyphylaxis with topical alpha-agonists means:
- An immediate allergic reaction on first use
- Gradual renal toxicity after weeks of use
- Rapidly diminishing response after repeated doses
- Enhanced effect with continued use
Correct Answer: Rapidly diminishing response after repeated doses
Q9. Which of the following is an imidazoline derivative commonly used as a topical decongestant?
- Pseudoephedrine
- Oxymetazoline
- Promethazine
- Diphenhydramine
Correct Answer: Oxymetazoline
Q10. A contraindication to systemic pseudoephedrine includes:
- Uncontrolled hypertension
- Mild seasonal allergies
- Mild renal impairment only
- Recent dental extraction
Correct Answer: Uncontrolled hypertension
Q11. Which adverse effect is more likely with systemic decongestants than topical ones?
- Local nasal irritation
- Systemic sympathetic stimulation (palpitations, insomnia)
- Immediate rebound congestion
- Local anesthetic effect
Correct Answer: Systemic sympathetic stimulation (palpitations, insomnia)
Q12. In pregnancy, which decongestant is generally considered safer for short-term use after risk–benefit assessment?
- Topical oxymetazoline with minimal systemic absorption
- High-dose oral pseudoephedrine throughout pregnancy
- Topical benzalkonium chloride alone
- Long-term daily phenylephrine
Correct Answer: Topical oxymetazoline with minimal systemic absorption
Q13. Which of the following best describes phenylephrine’s pharmacologic classification?
- Direct alpha-1 adrenergic agonist
- Beta-2 selective agonist
- Muscarinic antagonist
- Histamine H2 receptor antagonist
Correct Answer: Direct alpha-1 adrenergic agonist
Q14. The principal metabolic pathway for many sympathomimetic decongestants involves which enzyme system?
- CYP3A4-mediated oxidation only
- Monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT)
- Glucuronidation exclusively
- Acetylcholinesterase hydrolysis
Correct Answer: Monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT)
Q15. Which formulation factor increases systemic absorption of topical nasal decongestants?
- Use of metered-dose device with limited spray volume
- Applying to inflamed or ulcerated mucosa
- Using preservative-free saline only
- Low concentration and short contact time
Correct Answer: Applying to inflamed or ulcerated mucosa
Q16. Which sign would suggest overdose of systemic sympathomimetic decongestant?
- Hypotension and bradycardia
- Hyperthermia, severe agitation, tachycardia
- Excessive salivation and miosis
- Profound sedation and respiratory depression
Correct Answer: Hyperthermia, severe agitation, tachycardia
Q17. Which patient population requires caution due to risk of urinary retention with decongestant use?
- Young children with no urologic history
- Elderly males with benign prostatic hyperplasia
- Patients with seasonal allergies only
- Pregnant women in first trimester
Correct Answer: Elderly males with benign prostatic hyperplasia
Q18. Which nasal decongestant is known for long duration of action when applied topically (up to 12 hours)?
- Phenylephrine
- Oxymetazoline
- Naphazoline
- Pseudoephedrine
Correct Answer: Oxymetazoline
Q19. For B.Pharm counselling, how long is it generally recommended to use topical nasal decongestants to avoid rebound congestion?
- No more than 3–5 days
- At least 14 days continuously
- Indefinitely if symptoms persist
- Only once-weekly use is required
Correct Answer: No more than 3–5 days
Q20. A decongestant that primarily works indirectly by releasing endogenous norepinephrine is:
- Pseudoephedrine
- Oxymetazoline
- Phenylephrine
- Xylometazoline
Correct Answer: Pseudoephedrine
Q21. Which interaction is a clinical concern when combining decongestants with beta-blocker therapy?
- Complete neutralization leading to no effect
- Unopposed alpha-adrenergic vasoconstriction and increased blood pressure
- Enhanced bronchodilation causing hypokalemia
- Increased anticoagulant effect
Correct Answer: Unopposed alpha-adrenergic vasoconstriction and increased blood pressure
Q22. Which adverse effect is specifically linked to prolonged topical imidazoline use?
- Ototoxicity
- Rebound congestion (rhinitis medicamentosa)
- Renal failure
- Pancreatitis
Correct Answer: Rebound congestion (rhinitis medicamentosa)
Q23. Which statement about topical versus systemic decongestants is correct?
- Topical agents never cause systemic side effects
- Systemic agents provide local mucosal vasoconstriction faster than topical sprays
- Topical agents offer rapid onset with shorter systemic exposure compared with oral agents
- Systemic agents cannot raise blood pressure
Correct Answer: Topical agents offer rapid onset with shorter systemic exposure compared with oral agents
Q24. Which clinical laboratory parameter may need monitoring in chronic high-dose systemic decongestant use?
- Liver enzymes only in all cases
- Blood pressure and heart rate
- Serum potassium exclusively
- Complete blood count weekly
Correct Answer: Blood pressure and heart rate
Q25. Which is the best immediate management step for significant nasal decongestant-induced tachycardia and hypertension?
- Administer naloxone
- Supportive care, benzodiazepines for agitation, and antihypertensives if severe
- Give high-dose aspirin
- Administer insulin
Correct Answer: Supportive care, benzodiazepines for agitation, and antihypertensives if severe
Q26. Which of the following decongestants is least likely to cross the blood–brain barrier and cause central stimulation?
- Pseudoephedrine
- Phenylephrine (oral) with low oral bioavailability
- Ephedrine
- Amphetamine-like sympathomimetics
Correct Answer: Phenylephrine (oral) with low oral bioavailability
Q27. Which patient history would make you avoid recommending topical decongestant drops?
- Short-term acute nasal congestion for 24 hours
- Chronic nasal congestion for several weeks with prior frequent decongestant use
- Intermittent allergic rhinitis controlled with intranasal steroids
- Recent uncomplicated upper respiratory infection
Correct Answer: Chronic nasal congestion for several weeks with prior frequent decongestant use
Q28. Which property of xylometazoline contributes to its suitability for nasal spray formulations?
- Very short duration requiring hourly dosing
- High topical potency and prolonged vasoconstrictive action
- Strong antihistaminic activity
- Marked mucolytic action
Correct Answer: High topical potency and prolonged vasoconstrictive action
Q29. Which advice is appropriate when counseling a patient about correct nasal spray technique?
- Blow nose forcefully immediately after spraying
- Tilt head back sharply and use large volumes repeatedly
- Gently clear nostrils, keep head upright, aim spray away from septum, and use recommended dose
- Snort deeply to push spray into sinuses
Correct Answer: Gently clear nostrils, keep head upright, aim spray away from septum, and use recommended dose
Q30. Which research concern is relevant for B.Pharm students studying decongestants?
- Development of agents with higher systemic adrenergic activity
- Formulation strategies to minimize rebound congestion and systemic exposure
- Increasing preservatives to extend shelf-life regardless of mucosal effects
- Promoting indiscriminate OTC combination products
Correct Answer: Formulation strategies to minimize rebound congestion and systemic exposure
